Descripción de una serie de pacientes con miastenia gravis refractaria
| Autor: | Tomás Segura, A. Martínez-Martín, J.M. Pardal-Fernández, I. Díaz-Maroto, Jorge García-García |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
medicine.medical_specialty
business.industry Eculizumab medicine.disease Gastroenterology Myasthenia gravis 03 medical and health sciences 0302 clinical medicine Refractory Disease severity Quality of life Prednisone Internal medicine Cohort medicine Rituximab Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Neurología. 38:256-261 |
| ISSN: | 0213-4853 |
| DOI: | 10.1016/j.nrl.2020.08.016 |
| Popis: | INTRODUCTION Advances in the treatment of myasthenia gravis (MG) have improved quality of life and prognosis for the majority of patients. However, 10%-20% of patients present refractory MG, with frequent relapses and significant functional limitations. PATIENTS AND METHODS Patients with refractory MG were selected from a cohort of patients diagnosed with MG between January 2008 and June 2019. Refractory MG was defined as lack of response to treatment with prednisone and at least 2 immunosuppressants, inability to withdraw treatment without relapse in the last 12 months, or intolerance to treatment with severe adverse reactions. RESULTS We identified 84 patients with MG, 11 of whom (13%) met criteria for refractory MG. Mean (standard deviation) age was 47 (18) years; 64% of patients with refractory MG had early-onset generalised myasthenia (as compared to 22% in the group of patients with MG; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|